Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $43.87 million for the quarter. Rigel Pharmaceuticals has set its FY 2025 guidance at EPS.
Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last issued its earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.50. The firm had revenue of $57.60 million for the quarter, compared to analysts' expectations of $57.59 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. On average, analysts expect Rigel Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Rigel Pharmaceuticals Trading Up 3.4 %
RIGL traded up $0.64 during trading on Friday, reaching $19.36. 110,919 shares of the company were exchanged, compared to its average volume of 208,823. Rigel Pharmaceuticals has a 52 week low of $7.48 and a 52 week high of $29.82. The firm has a 50 day moving average of $18.93 and a 200 day moving average of $19.69. The stock has a market cap of $345.91 million, a P/E ratio of 138.30 and a beta of 1.34.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. B. Riley lifted their price objective on shares of Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a "neutral" rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $57.00 price objective on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 5th. StockNews.com cut Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 8th. Finally, Citigroup increased their price target on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $36.80.
Check Out Our Latest Report on Rigel Pharmaceuticals
Insider Buying and Selling at Rigel Pharmaceuticals
In related news, CEO Raul R. Rodriguez sold 4,952 shares of Rigel Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $103,595.84. Following the transaction, the chief executive officer now directly owns 243,854 shares in the company, valued at $5,101,425.68. The trade was a 1.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David A. Santos sold 2,125 shares of Rigel Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $44,455.00. Following the completion of the transaction, the executive vice president now directly owns 53,500 shares in the company, valued at $1,119,220. This represents a 3.82 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,113 shares of company stock valued at $190,644. 9.48% of the stock is owned by corporate insiders.
About Rigel Pharmaceuticals
(
Get Free Report)
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Further Reading
Before you consider Rigel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rigel Pharmaceuticals wasn't on the list.
While Rigel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
